<i>PAPPA2</i> mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and <scp>non‐small</scp> cell lung cancer-Reference-Cited by-同舟云学术

PAPPA2 mutation as a novel indicator stratifying beneficiaries of immune checkpoint inhibitors in skin cutaneous melanoma and non‐small cell lung cancer

Published:2022-07-10 Issue:9 Volume:55 Page:
ISSN:0960-7722
Container-title:Cell Proliferation
language:en
Short-container-title:Cell Proliferation

Author:

Dong Yiting¹,Zhao Lele²,Duan Jianchun¹,Bai Hua¹,Chen Dongsheng²,Li Si²,Yu Yangyang²,Xiao Mingzhe²,Zhang Qin²,Duan Qianqian²,Sun Tingting²,Qi Chuang²,Wang Jie¹,Wang Zhijie¹^ORCID

Affiliation:

1. State Key Laboratory of Molecular Oncology, Department of Medical Oncology, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital Chinese Academy of Medical Sciences and Peking Union Medical College Beijing China

2. The Medical Department, Jiangsu Simcere Diagnostics Co., Ltd, Nanjing Simcere Medical Laboratory Science Co., Ltd, The State Key Laboratory of Translational Medicine and Innovative Drug Development Jiangsu Simcere Diagnostics Co., Ltd Nanjing China

Funder

Natural Science Foundation of Beijing Municipality

Publisher

Wiley

Subject

Cell Biology,General Medicine

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1111/cpr.13283

Reference51 articles.

1. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries

2. Biomimetic Nanoerythrosome‐Coated Aptamer–DNA Tetrahedron/Maytansine Conjugates: pH‐Responsive and Targeted Cytotoxicity for HER2‐Positive Breast Cancer

3. Functionalizing framework nucleic‐acid‐based nanostructures for biomedical application;Zhang T;Adv Mater,2021